Skip to content

A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.

A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-005839-20-SE
Enrollment
Unknown
Registered
2006-11-08
Start date
2007-02-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-treatment during late pregnancy to reduce prolonged labour.

Interventions

Product Name: DF01 150 mg/ml solution for injection Pharmaceutical Form: Solution for injection Current Sponsor code: DF01 Other descriptive name: Low molecular weight derivative of heparin with low a

Sponsors

Dilafor AB
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) Healthy nulliparous females, 18-40 years of age with the gestation age confirmed by ultrasound. b) Normal singleton pregnancy c) Intact membranes d) In the opinion of the investigator, the subject will be able to comply with the requirements of the protocol, including ability to present for all required visits. e) Subject is capable of understanding and signing an informed consent form. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: a) Breech presentation including other abnormal presentations b) Vaginal bleeding in the last 10 weeks of the pregnancy c) Intercurrent illness (e.g. essential hypertension, diabetes, coagulation disorders) d) Pregnancy complications (e.g. hypertension in pregnancy, preeclampsia, hepatosis) e) Coagulation defects (prolonged APTT; Prothrombin complex (INR) > 1.2 ); Thrombocytes 30 kg/m2.

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the effect of pre-treatment with DF01 compared with placebo on labour delivery time, which is defined as time from cervical dilatation of at least 3 cm and 3 contractions of minimum one minute´s duration/10 minutes until partus in women with vaginal delivery.;Secondary Objective: To assess safety and tolerability of DF01, Complications of labour (e.g. caesarean section, instrumental delivery, vaginal tears, sphincter rupture, post-partum bleeding), Use of epidural anaesthesia, Foetal complications [e.g. cord artery pH 12 mmol/L , Apgar score < 7 at 5 minutes, neonatal intensive care unit (NICU) admission, neonatal diagnoses. ;Primary end point(s): Labour delivery time, defined as the time from cervical dilatation of at least 3cm and 3 contractions of minimum 1 minute´s duration/10 minutes until partus.

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026